Docoh
Loading...

BMRN Biomarin Pharmaceutical Inc. - Registered Shares

News

From Benzinga Pro
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
10 Jan 22
Biotech, News, Health Care, General
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.
BioMarin Announced 134-Participant Gene Therapy Study in Adults with Severe Hemophilia A Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis
9 Jan 22
News
BioMarin Pharmaceutical Inc.
BioMarin Granted FDA Orphan Designation For Treatment Of Hereditary Angioedema
20 Dec 21
News, FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=852221
BioMarin Pharma Reports Multi-Year Strategic Collab For Discovery, Development, Commercialization Of Adeno-Associated Virus Gene Therapies To Treat Genetic Cardivascular Disesases
16 Dec 21
Biotech, News, FDA, General
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today announced a multi-year
This Favorable Sign Appears On Biomarin Pharmaceutical's Chart
25 Nov 21
Markets, Movers, Trading Ideas
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
24 Nov 21
Markets, Movers, Trading Ideas
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Where Biomarin Pharmaceutical Stands With Analysts
22 Nov 21
Analyst Ratings
Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
22 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105
22 Nov 21
News, Price Target, Analyst Ratings
Credit Suisse analyst Tiago Fauth maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $100 to $105.
Morgan Stanley Maintains Equal-Weight on Biomarin Pharmaceutical, Raises Price Target to $90
22 Nov 21
News, Price Target, Analyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Equal-Weight and raises the price target from $82 to $90.
10 Biggest Price Target Changes For Monday
22 Nov 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
MKM Partners cut Activision Blizzard, Inc. (NASDAQ: ATVI) price target from $75 to $54. Activision Blizzard shares fell 0.9% to $61.80 in pre-market trading.
William Blair Upgrades Biomarin Pharmaceutical to Outperform
22 Nov 21
News, Upgrades, Analyst Ratings
William Blair analyst Tim Lugo upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Market Perform to Outperform.
SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115
22 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $112 to $115.
FDA Conditionally Approves Biomarin's Dwarfism Drug
19 Nov 21
Biotech, Long Ideas, News, Health Care, FDA, Movers, Trading Ideas, General
FDA Approves BioMarin's Vosoritide For Children With Most Common Form Of Dwarfism
19 Nov 21
Biotech, News, FDA, General
https://www.prnewswire.com/news-releases/fda-approves-first-drug-to-improve-growth-in-children-with-most-common-form-of-dwarfism-301429137.html
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
18 Nov 21
Biotech, Long Ideas, M&A, News, Health Care, Rumors, Movers, Trading Ideas, General
Entos, BioMarin Report Deal For Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform
15 Nov 21
Biotech, News, FDA, General
-- Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases EDMONTON, AB, Nov. 15, 2021 /PRNewswire/ - Entos Pharmaceuticals, Inc. (Entos), a
SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $112
15 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $108 to $112.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
2 Nov 21
Biotech, News, Penny Stocks, Health Care, Previews, Small Cap, FDA, Top Stories, Trading Ideas, General
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.

Press releases

From Benzinga Pro
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
14 Jan 22
Press Releases
NEW ORLEANS, Jan. 14, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an
Thinking about trading options or stock in BioMarin Pharmaceutical, Dell Technologies, Apple, ConocoPhillips, or Kroger?
10 Jan 22
Opinion, Press Releases
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMRN, DELL, AAPL, COP, and KR.
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis
9 Jan 22
Press Releases
SAN RAFAEL, Calif., Jan. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an
BioMarin to Participate in Two Virtual Investor Conferences in January
4 Jan 22
Press Releases
BioMarin to Present at Two Investor Conferences in January 2022SAN RAFAEL, Calif., Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief
BioMarin Update
2 Jan 22
Press Releases
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - January 2,
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. is Investigating BioMarin Pharmaceuticals on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
29 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioMarin Pharmaceuticals (NASDAQ:BMRN) on
Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN), InnovAge Holding Inc. (NASDAQGS: INNV), and Lightning eMotors, Inc. (NYSE: ZEV)
23 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQGM:AMRN) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against Amarin alleging that Defendants made false and
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN
22 Dec 21
Press Releases
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. (BMRN) Investors of Class Action
22 Dec 21
Press Releases
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain of
BMRN Final Deadline Today: Rosen, a Longstanding Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action - BMRN
22 Dec 21
Press Releases
New York, New York--(Newsfile Corp. - December 22, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) between January 13,
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN
21 Dec 21
Press Releases
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain of
BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
21 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) between January 13, 2020 and
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioMarin Pharmaceutical Inc. with Losses of $100,000 to Contact the Firm
21 Dec 21
Press Releases
LOS ANGELES, Dec.
BMRN FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important Wednesday Deadline in Securities Class Action - BMRN
20 Dec 21
Press Releases
New York, New York--(Newsfile Corp. - December 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) between January
BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
20 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
19 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain of its
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
16 Dec 21
News, Legal, Press Releases
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) between January 13, 2020 and
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN
16 Dec 21
Press Releases
New York, New York--(Newsfile Corp. - December 16, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
16 Dec 21
News, Contracts, Press Releases
SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN
15 Dec 21
Press Releases
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: